Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

PurposeEndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free i...

Descripción completa

Detalles Bibliográficos
Autores: Sestak, I, Martin, M, Dubsky, P, Kronenwett, R, Rojo, F, Cuzick, J, Filipits, M, Ruiz, A, Gradishar, W, Soliman, H, Schwartzberg, L, Buus, R, Hlauschek, D, Rodriguez-Lescure, A, Gnant, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p6995
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/6995
Access Level:acceso abierto
Palabra clave:Chemotherapy
Prediction
Breast cancer
EndoPredict
id ES_ae1bd2e6fccbd2323d20ab8a2d2c7545
oai_identifier_str oai:fisabio.fundanetsuite.com:p6995
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneSestak, IMartin, MDubsky, PKronenwett, RRojo, FCuzick, JFilipits, MRuiz, AGradishar, WSoliman, HSchwartzberg, LBuus, RHlauschek, DRodriguez-Lescure, AGnant, MChemotherapyPredictionBreast cancerEndoPredictPurposeEndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET+C).MethodsA total of 3746 women were included in this joint analysis. 2630 patients received 5years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET+C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET+C. Cox proportional hazard models were used for these analyses.ResultsEPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P<0.0001) as well as in those who received ET+C (HR 2.27 (1.99-2.59), P<0.0001). Women who received ET+C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin=5; 12% ET+C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-(interaction)=0.022).ConclusionsIn this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET+C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease.SPRINGER2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/6995BREAST CANCER RESEARCH AND TREATMENTISSN: 01676806ISSNe: 15737217reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p69952026-06-11T12:45:17Z
dc.title.none.fl_str_mv Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
title Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
spellingShingle Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
Sestak, I
Chemotherapy
Prediction
Breast cancer
EndoPredict
title_short Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
title_full Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
title_fullStr Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
title_full_unstemmed Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
title_sort Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
dc.creator.none.fl_str_mv Sestak, I
Martin, M
Dubsky, P
Kronenwett, R
Rojo, F
Cuzick, J
Filipits, M
Ruiz, A
Gradishar, W
Soliman, H
Schwartzberg, L
Buus, R
Hlauschek, D
Rodriguez-Lescure, A
Gnant, M
author Sestak, I
author_facet Sestak, I
Martin, M
Dubsky, P
Kronenwett, R
Rojo, F
Cuzick, J
Filipits, M
Ruiz, A
Gradishar, W
Soliman, H
Schwartzberg, L
Buus, R
Hlauschek, D
Rodriguez-Lescure, A
Gnant, M
author_role author
author2 Martin, M
Dubsky, P
Kronenwett, R
Rojo, F
Cuzick, J
Filipits, M
Ruiz, A
Gradishar, W
Soliman, H
Schwartzberg, L
Buus, R
Hlauschek, D
Rodriguez-Lescure, A
Gnant, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Chemotherapy
Prediction
Breast cancer
EndoPredict
topic Chemotherapy
Prediction
Breast cancer
EndoPredict
description PurposeEndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET+C).MethodsA total of 3746 women were included in this joint analysis. 2630 patients received 5years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET+C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET+C. Cox proportional hazard models were used for these analyses.ResultsEPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P<0.0001) as well as in those who received ET+C (HR 2.27 (1.99-2.59), P<0.0001). Women who received ET+C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin=5; 12% ET+C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-(interaction)=0.022).ConclusionsIn this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET+C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/6995
url https://fisabio.portalinvestigacion.com/publicaciones/6995
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv BREAST CANCER RESEARCH AND TREATMENT
ISSN: 01676806
ISSNe: 15737217
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416533671804928
score 15,811543

Similares en LA Referencia